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literature review was performed to identify relevant randomized controlled trials 
(RCTs). Data were extracted on study design and patient characteristics. Endpoints 
concerning efficacy were evaluated using network meta-analyses. Clinical response 
was defined as a decrease in Mayo score of ≥ 30% and ≥ 3 points, accompanied by a 
decrease in rectal bleeding score of ≥ 1 point or rectal bleeding score of 0 or 1. Clinical 
remission was defined as a total Mayo score of 2 points or lower, with no individ-
ual subscore exceeding 1 point. Mucosal healing was defined as absolute subscore 
for endoscopy of 0 or 1. Bayesian network meta-analyses (NMA) were conducted 
to evaluate each efficacy endpoint for TNF-naïve patients at the end of induction. 
All analyses were conducted using the OpenBUGS software package. Results: Six 
RCTs were identified from the literature. Similar clinical response was observed 
between the IFX and GOL treatment regimens (IFX 5mg: OR= 2.74, 95%Crl [1.48-5.1], 
IFX 10mg: 2.54 [1.37-4.73], GOL 200/100mg: OR= 1.7 [0.93-3.14], GOL 400/200mg: 1.95 
[1.05-3.58]) when compared to ADA 160/80mg. These similarities were also seen for 
mucosal healing (IFX 5mg: 2.66 [1.43-4.94], IFX 10mg: 2.57 [1.38-4.77], GOL 200/100mg: 
1.54 [0.83-2.85], GOL 400/200mg: 1.68 [0.91-3.10]). IFX demonstrated slightly greater 
clinical remission than GOL (IFX 5mg: 1.96 [0.80-4.65], IFX 10mg: 1.51 [0.61-3.62], GOL 
200/100mg: 1.55, 0.59-4.06], GOL 400/200mg: 1.47 [0.56-3.84]) when compared to ADA 
160/80mg. ConClusions: The NMA allowed the estimation and comparisons of 
clinical response, remission, and mucosal healing of interventions for UC evaluated in 
different RCTs. The findings suggest that the greatest induction of response in moder-
ate to severe UC patients is most likely achieved with IFX and GOL compared to ADA.
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objeCtives: To evaluate the comparative long-term efficacy of approved bio-
logic treatments for ulcerative colitis (UC), with a focus on golimumab(GOL), 
adalimumab(ADA), and infliximab(IFX). Methods: A systematic literature review 
identified 4 randomized controlled trials (RCTs) assessing the efficacy of IFX (5mg, 
10mg), ADA (160/80/40mg) and GOL (100mg, 50mg) as maintenance treatment for 
moderate to severe UC. Data were extracted on study design and patient character-
istics. Endpoints concerning efficacy were evaluated using network meta-analyses 
(NMA) within a Bayesian framework. Analyses were conducted to evaluate sus-
tained response to therapy at both the mid-point (week 30/36) and completion 
(week 52/54/60) of each trial. An additional sub-analysis was conducted because 
the PURSUIT trial design included a re-randomization of induction responders 
to placebo, GOL 50mg or GOL 100mg. This sub-analysis was limited to patients 
who received an induction regimen of GOL 200/100mg followed by 100mg during 
the maintenance period and induction non-responders who received 100mg as 
per protocol. All analyses were conducted using the OpenBUGS software pack-
age. Results: 4 RCTs were identified from the literature. Overall, IFX and GOL 
showed greater sustained response, remission and mucosal healing when compared 
to ADA 160/80/40mg. Between IFX and GOL, IFX doses showed greater remission at 
trial’s completion (IFX5mg OR= 2.04, 95%Crl 0.6-7.03; IFX10mg 1.96, 0.6-6.8; GOL50mg 
1.24, 0.4-3.9; GOL100mg 1.79, 0.6-5.4), response (IFX5mg 1.88,0.8-4.4; IFX10mg 1.73, 
0.7-4.1; GOL50mg, 1.38, 0.6-3.1; GOL100mg 1.45, 0.6-3.3) and mucosal healing (IFX5mg 
1.51,0.7-3.4; IFX10mg 1.53, 0.7-3.5; GOL50mg, 1.38, 0.6-3.3; GOL100mg 1.38, 0.6-3.2. 
During the sub-analyses, GOL100mg and both IFX doses demonstrated greater sus-
tained response and sustained remission when compared to ADA 160/80/40mg. 
Sustained mucosal response increased for IFX 5mg and IFX10mg but decreased for 
GOL100mg. ConClusions: Based on indirect comparison of RCT evidence, IFX 
and GOL are more efficacious to induce and maintain long term response than ADA 
among moderate to severe UC patients.
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objeCtives: To systematically identify and review published evidence on the efficacy 
of antidepressants (tricyclic antidepressants (TCA) and selective serotonin inhibi-
tors (SSRI)) for irritable bowel syndrome (IBS). Methods: A systematic search of the 
medical literature was conducted using PubMed, Embase, and Cochrane databases. 
Search terms included ‘irritable bowel syndrome’, ‘spastic colon’, ‘irritable colon’, 
‘functional diseases, colon’ and a mixture of agent terms – including antidepressants, 
tricyclic, and SSRIs. Randomised placebo-controlled trials evaluating the efficacy of 
antidepressants (SSRIs and TCAs) in adult patients with IBS were eligible for inclusion. 
Exclusion criteria included absence of placebo arm, patients< 18 years of age, and dual 
publication. Results: A total of 628 unique titles and abstracts were retrieved; 579 
records were excluded upon title (or abstract) review and 31 upon full-text review. The 
final review included 17 studies, 10 reporting on TCAs, 6 on SSRIs, and 1 comparing 
both an SSRI and a TCA vs. placebo, and assessed the methodological compliance of 
each included study with that used in regulatory submissions. In these studies, the 
majority of patients had diarrhea, and only one study, (on SSRIs) reported specifically 
on IBS-C. Treatment duration ranged from 4-12 weeks. A range of outcomes were 
reported, most commonly global symptom relief, and improvements in abdominal 
pain/discomfort. Three studies reported on quality of life, while no studies reported 
specifically on treatment satisfaction. Most outcomes did not align well with those 
now required for FDA and EMA regulatory approval. Across all studies, patient drop-
outs were common, and reporting on per-protocol and intention-to-treat (ITT) popu-
lations varied and in many cases was not explicitly reported. ConClusions: The 
evidence base was of low quality, making estimates of effect very uncertain. Data for 
the efficacy of antidepressants in IBS subtypes is especially limited. Further studies 
are required to support the off-label use of antidepressants in IBS-C.
did not have the disease, demonstrated by a crude relative risk of 6.06 in England 
(37.6% vs. 6.2%), 2.68 in The Netherlands (19.0% vs. 7.1%), and 1.97 in Spain (14.9% vs. 
7.5%). When controlling for covariates, predictive models found a considerable impact 
of hospital-onset CDI on mortality with odds ratios of 2.57 for England (p< 0.001), 
1.88 for The Netherlands (p< 0.001) and 1.33 for Spain (p< 0.001). ConClusions: This 
research demonstrates the significant impact of CDI on hospital mortality and the 
need for more preventative measures within the hospital setting. Further research 
using death certificate data could improve the predictive results of models by ensur-
ing that causal effects of CDI are accurately accounted for.
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objeCtives: The inflammatory bowel diseases (IBD) are characterized by chronic 
inflammation of the gastrointestinal tract; the irritable bowel syndrome (IBS) is a func-
tional disorder (prevalence 10%-20%). They present overlapping symptoms, making 
diagnosis difficult in primary care. Endoscopy is the gold standard for IBD, but it often 
turns negative due to IBD’s low prevalence, it is expensive, uncomfortable and risky 
for the patient. F-Calprotectin is a marker of intestine inflammation: as IBD patients 
exhibit levels higher than the general population and IBS patients, F-Calprotectin can 
be used to rule out IBD. The only CE evaluation on F-Calprotectin has been published 
by NHS (CEP09041, 2010); based on new evidence, we propose a refined model to 
evaluate the CE of F-Calprotectin compared to the standard pre-endoscopic sero-
logic test (CRP+ESR) to distinguish IBD from IBS in the UK and Spain. Methods: 
F-Calprotectin sensitivity (0.96) and specificity (0.96) were evaluated from a meta-
analysis performed in March 2013; CRP+ESR sensitivity (0.35) and specificity (0.73), 
and the costs come from CEP09041. Published HRQoL values for IBD and IBS were 
transformed in QALYs with transfer-to-utility techniques. The outcomes included 
cost savings, cost per QALY. Uncertainty was addressed with a probabilistic sensitiv-
ity analysis. Results: Results for UK show that F-Calprotectin is CE with respect 
to CRP+ESR: a) it results in more corrected IBD diagnoses at a lower price (it costs 
113£ and 85€ less per patient); b) it reduces the number of unnecessary endoscopies, 
increasing the number of correctly diagnosed IBD (N= 59) and IBS (N= 195) patients; 
c) it brings about a QALY gain per patient equal to 0.0034QALYs; in the UK, the ICER 
of the CRP+ESR diagnostic strategy is 47,783£ (25,941€ for Spain), falling well outside 
the cost-effectiveness bounds (20,000–30,000£ per additional QALY). ConClusions: 
F-Calprotectin is CE to rule out IBD in primary care in UK and Spain.
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objeCtives: To systematically appraise the literature on the accuracy of four widely 
used tests to diagnose Pancreatic Exocrine Insufficiency (PEI) secondary to chronic 
pancreatitis (CP), gastrointestinal/pancreatic surgery or pancreatic cancer in Spain, 
namely: coefficient of fat absorption (CFA); mixed 13C-triglyceride breath test (MTG); 
fecal elastase-I (FE-I); and serum nutritional markers (SNM). Methods: A system-
atic review of the literature (March, 2013) was performed (MedLine/PubMed, Cochrane 
Library, CRD, MEDION, ARIF, MEDES, IBECS, ISI WOK, SCOPUS), based on the Cochrane 
and NHS Centre for Reviews and Dissemination recommendations for reviewing 
diagnostic test accuracy studies. Expert validation of the review strategy and results 
were achieved by two consensus meetings. Results: Out of 13.379 publications, 16 
from the systematic search and 3 from hand-search were reviewed: 11 in CP and 8 
in cancer/surgery patients. Fourteen of these used the secretin/cerulein test as the 
reference standard. According to experts, CFA is the gold standard for PEI diagnosis 
(assumed accuracy 100%). 4 publications using CFA as the reference standard were 
selected: FE-I sensitivity and specificity in 58 CP (cutoff < 218μ g/g) and 40 cancer/
surgery patients (cutoff 200μ g/g) were 68% and 98%, and 91% and 35%, respectively. 
MTG was ≥ 90% sensitive and specific in all populations (63 patients), experts con-
sidered this a good reference standard. Sensitivity and specificity for SNM vs. MTG 
were 80% and 81%, respectively and considered by experts as similarly accurate in 
the cancer/surgery population. ConClusions: This is the first systematic review 
to confirm the accuracy of four diagnostic tests for PEI in CP and cancer/surgery 
patients, with the final selection of results being based on expert consensus to 
ensure that the data are representative of Spanish clinical practice. These data, 
together with resource use and cost information from clinical practice will feed an 
economic tool to assess the cost of PEI diagnosis in Spain.
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objeCtives: To evaluate the comparative efficacy of approved biologic treatments 
for ulcerative colitis (UC), with a focus on golimumab(GOL), adalimumab(ADA), and 
infliximab(IFX) in the induction periods of clinical trials. Methods: A systematic 
